The Effects of Dry Cupping on Overhead College Athletes

This study look at the effects of dry cupping on range of motion and pain symptoms in forty overhead athletes involved in sports such as softball, baseball, and volleyball. Two groups were tested during this study, a control group and an experimental group. Both groups were tested before the treatment and after the treatment using a visual analog scale for pain symptoms and a goniometer for range of motion changes (Yim et al., 2017). A dry cupping therapy treatment was applied the shoulder muscles, lattimus dorsi, rotator cuff muscles, and the muscles around the scapular for ten minutes each session (Gregory et al., 2020). A manual suction and ten plastic circular cups of different sizes were used on the subjects with a lubricant to allow the cups to slide and/or stick.https://digitalcommons.gardner-webb.edu/exercise-science-research-proposal-posters/1182/thumbnail.jp

Excessive Post- Exercise Oxygen Consumption (EPOC) Following a Twenty-Minute Submaximal Cycle Test

According to McArdle et al. (2015), Excessive Post-Exercise Oxygen Consumption (EPOC) computes the total oxygen consumed in recovery minus the total oxygen consumed at rest during the recovery period. According to McArdle et al. (2015), VO2 mL/kg/min is defined as maximal oxygen consumption. According to McArdle et al. (2015), respiratory exchange ratio (RER) is the ratio of carbon dioxide produced to oxygen consumed under rest and steady-state conditions with little reliance on anaerobic metabolism. According to Dr. et al. (2004), EPOC is also known as O2 deficit and was used as a measure of anaerobic metabolism during exercise. According to McArdle et al. (2015), there are two forms that are used to help determine EPOC for exercise and recovery: active recovery and passive recovery. Active recovery is defined as ‘cooling down’ or ‘tapering off’ and passive recovery is where an individual usually lies down presuming that total inactivity reduces the resting energy requirements and thus ‘frees’ oxygen to fuel the recovery process (McArdle et al., 2015). During this study, the individual performed a passive recovery. V̇O2 is the maximal oxygen consumption that an individual utilizes during an intense exercise (McArdle et al., 2015). Heart rate is the number of times the heart beats per minute which is based on the number of contractions of the ventricles. Pulmonary Ventilation (VE) describes the process of moving and exchanging ambient air with air in the lungs (McArdle et al., 2015). The purpose of this study was to determine if EPOC could be assessed in a 20–32-year-old college student 10 minutes after a sub max cycling test is performed. It was hypothesized that EPOC can be assessed 10 minutes after a submaximal cycle test is performed.https://digitalcommons.gardner-webb.edu/exercise-science-research-proposal-posters/1138/thumbnail.jp

The Effects of Cardio Warm Up (CW) and Dynamic Warm Up (DW) on Sprint Time in Trained Individuals

According to Sander et al., (2013) a warmup to increase sprint time should include nonspecific running, coordination exercises, stretching, and acceleration runs. According to Zhou et al., (2020), an investigation into multiple studies found that aspects such as arm motion, takeoff angle, standing posture, warm up exercises, and handheld weights improved sprint times. The purpose of this study was to determine how a dynamic warmup compared to a cardio warm up will improve sprint time in trained collegiate D-I athletes. It was hypothesized that with the addition of a broad jump at the end of a standardized dynamic warm up, that trained individuals will show an increased sprint time performance in a 20-yard sprint test compared to a cardio warm up.https://digitalcommons.gardner-webb.edu/exercise-science-research-proposal-posters/1139/thumbnail.jp

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Summary Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886) we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralising antibody titres (NAbT) using a live virus microneutralization assay against wild-type (WT), Delta, Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titres and T cell responses after the fourth vaccine dose increases compared to those after the third vaccine dose. Patients who received B cell-depleting therapies within 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS). Although TLS have been found to correlate with improved patient survival and response to immune checkpoint blockade (ICB), the underlying mechanisms of this association remain elusive. Here we investigate lung-resident B cell responses in patients from the TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) and other lung cancer cohorts, and in a recently established immunogenic mouse model for lung adenocarcinoma. We find that both human and mouse lung adenocarcinomas elicit local germinal centre responses and tumour-binding antibodies, and further identify endogenous retrovirus (ERV) envelope glycoproteins as a dominant anti-tumour antibody target. ERV-targeting B cell responses are amplified by ICB in both humans and mice, and by targeted inhibition of KRAS(G12C) in the mouse model. ERV-reactive antibodies exert anti-tumour activity that extends survival in the mouse model, and ERV expression predicts the outcome of ICB in human lung adenocarcinoma. Finally, we find that effective immunotherapy in the mouse model requires CXCL13-dependent TLS formation. Conversely, therapeutic CXCL13 treatment potentiates anti-tumour immunity and synergizes with ICB. Our findings provide a possible mechanistic basis for the association of TLS with immunotherapy response

The evolution of lung cancer and impact of subclonal selection in TRACERx

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer genes were under significant subclonal selection, including classical tumour initiators such as TP53 and KRAS. We defined evolutionary dependencies between drivers, mutational processes and whole genome doubling (WGD) events. Despite patients having a history of smoking, 8% of lung adenocarcinomas lacked evidence of tobacco-induced mutagenesis. These tumours also had similar detection rates for EGFR mutations and for RET, ROS1, ALK and MET oncogenic isoforms compared with tumours in never-smokers, which suggests that they have a similar aetiology and pathogenesis. Large subclonal expansions were associated with positive subclonal selection. Patients with tumours harbouring recent subclonal expansions, on the terminus of a phylogenetic branch, had significantly shorter disease-free survival. Subclonal WGD was detected in 19% of tumours, and 10% of tumours harboured multiple subclonal WGDs in parallel. Subclonal, but not truncal, WGD was associated with shorter disease-free survival. Copy number heterogeneity was associated with extrathoracic relapse within 1 year after surgery. These data demonstrate the importance of clonal expansion, WGD and copy number instability in determining the timing and patterns of relapse in non-small cell lung cancer and provide a comprehensive clinical cancer evolutionary data resource

The evolution of non-small cell lung cancer metastases in TRACERx

Metastatic disease is responsible for the majority of cancer-related deaths. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of initial diagnosis. Simulations suggested that early metastatic divergence more frequently occurred at smaller tumour diameters (less than 8 mm). Single-region primary tumour sampling resulted in 83% of late divergence cases being misclassified as early, highlighting the importance of extensive primary tumour sampling. Polyclonal dissemination, which was associated with extrathoracic disease recurrence, was found in 32% of cases. Primary lymph node disease contributed to metastatic relapse in less than 20% of cases, representing a hallmark of metastatic potential rather than a route to subsequent recurrences/disease progression. Metastasis-seeding subclones exhibited subclonal expansions within primary tumours, probably reflecting positive selection. Our findings highlight the importance of selection in metastatic clone evolution within untreated primary tumours, the distinction between monoclonal versus polyclonal seeding in dictating site of recurrence, the limitations of current radiological screening approaches for early diverging tumours and the need to develop strategies to target metastasis-seeding subclones before relapse